Opko bid in GHD skewed by outlier; analysis to tell true result
By Randy Osborne
Staff Writer
Staff Writer
A weight-losing outlier in the phase III trial's placebo group "should have been picked up earlier or should have been thrown out before we unblinded," Opko Health Inc.'s vice president, Steven Rubin, told BioWorld Today.
